Mylan to buy Aspen’s European thrombosis business for €642m

This article was originally published here

Under the deal, Mylan will acquire Aspen’s portfolio that includes injectable anticoagulants marketed in Europe under the brand names and variations of the brand names such as Arixtra,

The post Mylan to buy Aspen’s European thrombosis business for €642m appeared first on Pharmaceutical Business review.